Indication and results of thermal ablation therapies for hepatocellular carcinoma

Abstract

We analyzed the survival rates, local recurrence rates, and another recurrence rates for patients with solitary hepatocellular carcinoma who received thermal ablation therapies as primary treatment (naive patients). In these 89 patients, 35 cases were ablated by percutaneous radiofrequency ablation (PRFA), 32 were treated by laparoscopic microwave coagulation (LMCT), and 22 were treated by percutaneous microwave coagulation (PMCT). 5-year survival rates were 87% in PRFA, 56% in LMCT, 76% in PMCT. The differences of survival rates were not statistically significant among PRFA, LMCT, and PMCT. 5-year local recurrence rates were 49%, 26%, and 44%, consecutively. No differences were found between therapies. 5-year another recurrence rates were 100%, 81%, and 80%, consecutively. No differences were found statistically.